| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2110-2118.)
© 2007 American Heart Association, Inc.
Epidemiology |
From the Donald W. Reynolds Center for Cardiovascular Research and the Center for Cardiovascular Disease Prevention (S.M., N.C., J.E.B., P.M.R.), Leducq Center for Molecular and Genetic Epidemiology (S.M., P.M.R.), and Divisions of Preventive Medicine (S.M., N.C., J.E.B., P.M.R., I.-M.L.) and Cardiovascular Medicine (S.M., P.M.R.), Brigham and Womens Hospital, Harvard Medical School, and the Department of Epidemiology, Harvard School of Public Health (N.C., J.E.B., P.M.R., I.-M.L.), Boston, Mass.
Correspondence to Samia Mora, MD, MHS, Brigham and Womens Hospital, 900 Commonwealth Ave E, Third Floor, Boston, MA 02215. E-mail smora2{at}partners.org
Received July 24, 2007; accepted September 14, 2007.
| Abstract |
|---|
|
|
|---|
Methods and Results— In a prospective study of 27 055 apparently healthy women, we measured baseline levels of hemoglobin A1c, traditional lipids (total, low-density lipoprotein, and high-density lipoprotein cholesterol), novel lipids [lipoprotein(a) and apolipoprotein A1 and B-100], creatinine, homocysteine, and inflammatory/hemostatic biomarkers (high-sensitivity C-reactive protein, fibrinogen, soluble intracellular adhesion molecule-1) and used womens self-reported physical activity, weight, height, hypertension, and diabetes. Mean follow-up was 10.9±1.6 years, and 979 incident CVD events occurred. The risk of CVD decreased linearly with higher levels of activity (P for linear trend <0.001). Using the reference group of <200 kcal/wk of activity yielded age- and treatment-adjusted relative risk reductions associated with 200 to 599, 600 to 1499, and
1500 kcal/wk of 27%, 32%, and 41%, respectively. Differences in known risk factors explained a large proportion (59.0%) of the observed inverse association. When sets of risk factors were examined, inflammatory/hemostatic biomarkers made the largest contribution to lower risk (32.6%), followed by blood pressure (27.1%). Novel lipids contributed less to CVD risk reduction compared with traditional lipids (15.5% and 19.1%, respectively). Smaller contributions were attributed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine and creatinine had negligible effects (<1%).
Conclusions— The inverse association between physical activity and CVD risk is mediated in substantial part by known risk factors, particularly inflammatory/hemostatic factors and blood pressure.
Key Words: cardiovascular diseases epidemiology exercise risk factors women
| Introduction |
|---|
|
|
|---|
Clinical Perspective p 2118
The relative contribution of these various risk factors, representing a number of physiological pathways, to the activity-related risk reduction in CVD is unknown. In addition, newly recognized CVD risk factors, in particular those relating to inflammation and hemostasis, also are modified favorably with physical activity.13–18 This likely represents an additional mechanistic pathway through which physical activity decreases CVD risk. Therefore, the aim of the present study was to quantify the contribution of traditional and novel risk factors to the activity-related reduction in CVD.
| Methods |
|---|
|
|
|---|
45 years of age who were free of self-reported CVD and cancer at study entry (1992 to 1995). Women gave written informed consent and completed questionnaires at the time of enrollment on demographics, anthropometrics, medical history, medications, and lifestyle factors. They also were asked to provide a blood sample; 28 345 women did so. For this study, we excluded women with missing data on physical activity or body mass index (n=544) or missing information on the traditional or novel biomarkers of interest (n=433), leaving 27 055 women for analysis. The study was approved by the Institutional Review Board of the Brigham and Womens Hospital (Boston, Mass).
Assessment of Physical Activity and CVD Risk Factors
Physical activity was assessed at study entry with a questionnaire that has been shown to be valid and reliable.22 The correlation of activity reported on the questionnaires compared with activity diaries kept for 4 weeks over a year was 0.62.22 Participants were asked to estimate the average time per week over the past year spent on 8 groups of recreational activities and the number of flights of stairs climbed daily.23 A metabolic equivalent task (MET) score was assigned to each activity on the basis of its energy cost. We estimated the energy expended on each of the above groups of activities and summed over all activities to estimate the total energy expended on physical activity (kcal/wk). We used kilocalories as the unit of energy expenditure because this unit is widely understood by physicians and patients. However, body weight is used in the computation of energy expenditure in kilocalories per week (ie, for the same activity, a heavier person expends more kilocalories than a lighter person). Thus, we repeated analyses using energy expenditure estimated in MET-hours, a unit that is independent of body weight (ie, for the same activity, heavier and lighter persons expend the same MET-hours).
At study entry, participants also reported information on smoking, diet, menopausal status, hormone use, weight, height, blood pressure, history of hypertension (blood pressure
140/90 mm Hg or use of antihypertensive medication) and diabetes, and family history.
Laboratory Measurements
EDTA blood samples were obtained at the time of enrollment in the WHS and stored in vapor-phase liquid nitrogen (–170°C). Hemoglobin A1c was assessed with an immunoturbidimetric assay (Roche Diagnostics, Indianapolis, Ind). Total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol was assayed with reagents from Genzyme Corp (Cambridge, Mass) and Roche Diagnostics. Lipoprotein(a) was measured with an immunoturbidimetric assay (Roche Diagnostics) with reagents and calibrators from Denka Seiken (Tokyo, Japan). Apolipoproteins A1 and B-100 were measured with immunoturbidimetric assays (DiaSorin, Stillwater, Minn). Creatinine was measured by a rate-blanked method that is based on the Jaffé reaction using Roche Diagnostics reagents. An enzymatic assay was used to measure homocysteine (Catch Inc, Seattle, Wash). High-sensitivity C-reactive protein (CRP) was measured with a high-sensitivity immunoturbidimetric assay on the Hitachi 917 analyzer (Roche Diagnostics) using reagents and calibrators from Denka Seiken. Fibrinogen was measured with an immunoturbidimetric assay (Kamiya Biomedical, Seattle, Wash); soluble intracellular adhesion molecule-1 (ICAM-1) was measured with an ELISA assay (R&D Systems, Minneapolis, Minn).
Ascertainment of CVD Events
The primary end point of interest was a composite end point of incident CVD (nonfatal myocardial infarction [MI], nonfatal ischemic stroke, percutaneous coronary intervention, coronary artery bypass grafting, or cardiovascular death). Other end points were incident coronary heart disease (CHD; nonfatal MI, percutaneous coronary intervention, coronary artery bypass grafting, or coronary death) and the individual CVD end points. Women reported the end points of interest on follow-up questionnaires every 6 or 12 months, and confirmed events were included in analyses as previously described.21
Statistical Analysis
Statistical analyses were performed with STATA version 8.2 (STATA Corp, College Station, Tex). We categorized participants into approximate quartiles of energy expenditure (<200, 200 to 599, 600 to 1499, and
1500 kcal/wk); the highest activity category corresponds to
5 hours of moderate-intensity activity per week.23 Cox proportional-hazard regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) according to these activity groups. Tests for linear trend were performed using the median value for each activity group. All probability values were 2 tailed.
To examine the extent to which various CVD risk factors contributed to the risk reduction in events associated with activity, we initially considered each risk factor separately in a model that adjusted for age and randomized treatment assignment. We considered the magnitude of change in the HRs for the most active women compared with the least with and without adjustment for each risk factor. A larger change in the HR toward the null implies a larger mediating effect of that risk factor on the activity-related reduction in CVD.
Then, on an a priori basis, we grouped together a set of variables that are generally considered to be potential confounders rather than mediators (smoking; dietary intake of alcohol, fruits, and vegetables; consumption of saturated fat and fiber; menopause; hormone use; and parental history of MI before 60 years of age). We included this set of variables, together with age and randomized treatment assignment, in a single model, referring to this model as the basic model.
Also on an a priori basis, we grouped other CVD risk factors generally considered to be potential mediators into sets of risk factors on the basis of their pathophysiological effects. Blood pressure and the presence or absence of hypertension were combined as 1 set. Hemoglobin A1c and the presence or absence of diabetes were combined as another set. To consider the combined effect of traditional lipids, we combined total, LDL, and HDL cholesterol into 1 set, with a similar analysis for novel lipids [lipoprotein(a), apolipoprotein A1 and B-100]. High-sensitivity CRP, fibrinogen, and soluble ICAM-1 were considered as a group related to inflammatory and hemostatic pathways. Finally, body mass index and homocysteine were examined separately.
To examine the extent to which CVD risk factors potentially mediated the effect of activity on incident CVD, we next added these risk factors, 1 set at a time, to the basic model and examined the magnitude of change in the HRs for the most active women compared with the least without (basic model) and with adjustment for each set of risk factors (adjusted model). Finally, we performed a fully adjusted analysis that included all the CVD risk factors simultaneously. The proportion of CVD risk reduction explained by each set of CVD risk factors was computed as follows24,25: (HRbasic model–HRadjusted model)/(HRbasic model–1)x100%.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
During a mean follow-up of 10.9±1.6 years, a total of 979 first CVD events occurred, including 640 CHD events (253 MIs, 398 percutaneous coronary interventions, and 219 coronary artery bypass grafts) and 266 ischemic strokes. The risk of incident CVD decreased linearly with higher levels of activity (P for linear trend <0.001; Table 2). Using the reference group of <200 kcal/wk of activity and after adjusting for age and randomized-treatment assignment, we found relative risk reductions associated with 200 to 599, 600 to 1499, and
1500 kcal/wk of 27%, 32%, and 41%, respectively. In separate Cox regression models that considered each risk factor variable, 1 at a time, and adjusted for age and treatment assignment (Table 2), there was some attenuation noted in the HRs comparing the most active women with the least active before and after adjustment for all variables, except for creatinine, lipoprotein(a), and postmenopausal status/hormone use. However, when all risk factors were combined in 1 model, the HR comparing the most active women with the least active was substantially attenuated (after adjustment for all risk factors: HR, 0.90; 95% CI, 0.73 to 1.11; after adjusting for only age and treatment assignment: HR, 0.59; 95% CI, 0.49 to 0.71), and the linear trend across activity levels was no longer significant (P for linear trend=0.37).
|
Next, to determine the extent to which the reduced risk of CVD associated with activity was influenced by potential mediators representing various physiological pathways, each set of mediators was added, 1 set at a time, to the basic model (Table 3, top). For CVD, the addition of blood pressure/hypertension resulted in an attenuation of the inverse relation, which became nonsignificant (P for trend=0.09), with similar results for the inflammatory/hemostatic biomarkers (P for trend=0.10). The addition of body mass index, hemoglobin A1c/diabetes, traditional lipids, and novel lipids, 1 set at a time, resulted in smaller attenuations in the inverse relation between activity and CVD (all P for trend
0.05). Adding all sets of risk factors simultaneously to the basic model resulted in further attenuation of the HRs, and no significant associations were observed (P for trend=0.36).
|
For CHD, a broadly similar pattern was observed (Table 3, bottom). Unlike CVD, there remained a borderline-significant inverse association with CHD after adjustment for all sets of risk factors (P for trend=0.05).
The associations of activity with nonfatal MI, percutaneous coronary intervention, and coronary artery bypass grafting, when examined as separate end points, are shown in Table 4. When the sets of potential mediators were added to the basic model, the effect of physical activity was attenuated in a manner similar to that seen with CHD. The association of activity with ischemic stroke was nonlinear (corresponding age- and treatment-adjusted HRs and 95% CIs: 1.00, 0.68 [95% CI, 0.49 to 0.95], 0.69 [95% CI, 0.50 to 0.95], and 0.72 [95% CI, 0.51 to 1.01], respectively; P for trend=0.16).
|
Finally, we computed the proportion of the physical activity–related reduction in CVD or CHD events explained by each set of potential mediators (Figure). A large proportion (59.0%) of the inverse relation between physical activity and CVD risk was explained by the potential mediators that we investigated. When examined as sets of risk factors, inflammatory/hemostatic biomarkers were the largest contributors to lower risk (32.6%), followed by blood pressure (27.1%). Novel lipids [lipoprotein(a), apolipoprotein A1 and B-100] contributed less to CVD risk reduction than traditional lipids (total, LDL, and HDL cholesterol): 15.5% and 19.1%, respectively. Smaller contributions were attributed to body mass index (10.1%) and hemoglobin A1c/diabetes (8.9%), whereas homocysteine had negligible effects (<1%). A similar but smaller pattern was observed for CHD (35.5% of the CHD event risk reduction explained by risk factors compared with 59.0% for CVD).
|
We repeated our analyses (Figure, B), calculating activity expenditure in MET-hours per week instead of kilocalories per week. Almost identical results were obtained except for body mass index, the contribution of which increased from 10.1% to 21.9%, and hemoglobin A1c/diabetes, which increased from 8.9% to 12.2%.
| Discussion |
|---|
|
|
|---|
The beneficial effect of physical activity was stronger for CHD compared with CVD in this study, but the relative contributions of potential mediators were proportional and qualitatively similar. Previous studies have noted nonlinear associations or weak or positive associations between activity and stroke,26,27 as did we.
Prior studies have demonstrated favorable effects of physical activity on traditional risk factors.9,28–30 Although some individuals may experience large changes in risk factors with exercise,31 most individuals experience modest short-term changes, on the order of 2% to 5%.8–12 The effect of exercise on inflammatory factors has been recognized more recently.13,17,32 Acute bouts of exercise result in a transient, mostly proinflammatory, several-fold increase in acute-phase reactants and cytokines,33 proportional to the amount of exercise and muscle injury.32
In contrast, regular activity also has been associated with a chronic antiinflammatory effect, with moderate (
20% to 30%) reductions in CRP and soluble ICAM and vascular adhesion molecules.34,35 We previously demonstrated that in this population of women, the highest versus lowest level of activity was associated with
43% lower high-sensitivity CRP level, which was mildly attenuated to 37% after adjustment for the other risk factors, including body mass index.18 The mechanisms underlying the chronic antiinflammatory and hemostatic effects of exercise are not well defined and are only partially related to body weight.18,36 Other explanations include possible effects on proatherogenic adipokines, insulin-sensitizing pathways, or the hemostatic and antioxidant functions of the coronary endothelium.32,37 Regular exercise attenuates the age-associated increase in oxidative stress and nuclear factor-
B activation in animals38 and reduces toll-like receptor 4 signaling, which may explain the chronic antiinflammatory effect of exercise.39–40
Several limitations of the present study warrant consideration. Physical activity and several of the risk factors were assessed by self-report. It is possible that more precise assessment of these factors may have resulted in a different contribution of these variables to the reduction in CVD risk. The study design was observational but prospectively collected. We did not have information on other variables that are favorably influenced by physical activity, such as those related to heart rate or autonomic balance,41 baseline waist circumference or insulin sensitivity,42 and nitric oxide–dependent endothelial activity,43 so we could not evaluate their contributions to the inverse relation between physical activity and CVD risk.
This study also has several strengths, including the large number of women investigated, detailed information on physical activity, a wide range of traditional and novel CVD risk factors, and the long duration of follow-up for the various cardiovascular end points.
In summary, to the best of our knowledge, this is the first study to attempt to quantify the relative importance of potential underlying mechanisms through which higher levels of physical activity are associated with lower risk of CVD events. In this study, we have identified potential underlying mechanisms through which even moderate levels of physical activity (at least 600 kcal/wk, or the equivalent of just over 2 h/wk of brisk walking, consistent with current guideline recommendations)44 are associated with lower risk of clinically important CVD events. Modest changes in known CVD risk factors, particularly those relating to inflammation/hemostasis and blood pressure, account for a substantial portion of the benefit of physical activity on CVD risk and thus may have important downstream consequences for the primary prevention of CVD.
| Acknowledgments |
|---|
The research for this article was supported by grants from the Donald W. Reynolds Foundation, Leducq Foundation, and Doris Duke Charitable Foundation. The WHS is supported by grants HL-43851 and CA-47988 from the National Heart, Lung, and Blood Institute, grants from the National Cancer Institute, and philanthropic support from Elisabeth and Alan Doft and their family. Dr Mora is supported by the Sandra Daugherty Foundation and grant 0670007N from the American Heart Association. The funding agencies played no role in the design, conduct, data management, analysis, or manuscript preparation related to this article.
Disclosures
Dr Ridker is listed as a coinventor on patents held by the Brigham and Womens Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease. Dr Lee has served as a consultant for Virgin Life Care and sits on its Scientific Advisory Board. The other authors report no conflicts.
| References |
|---|
|
|
|---|
2. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002; 347: 716–725.
3. Paffenbarger RS Jr, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N Engl J Med. 1986; 314: 605–613.[Abstract]
4. Blair SN, Kohl HW 3rd, Paffenbarger RS Jr, Clark DG, Cooper KH, Gibbons LW. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA. 1989; 262: 2395–2401.
5. Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study. Arch Intern Med. 1998; 158: 1499–1505.
6. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol. 2002; 156: 832–841.
7. Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004; 351: 2694–2703.
8. Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001; 33: S502–S515.
9. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002; 347: 1483–1492.
10. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc. 2001; 33: S484–S492.
11. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002; 136: 493–503.
12. Thompson PD, Crouse SF, Goodpaster B, Kelley D, Moyna N, Pescatello L. The acute versus the chronic response to exercise. Med Sci Sports Exerc. 2001; 33: S438–S445.
13. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation. 2002; 105: 1785–1790.
14. Abramson JL, Vaccarino V. Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med. 2002; 162: 1286–1292.
15. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute–National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the pathophysiology of obesity-associated cardiovascular disease. Circulation. 2002; 105: 2923–2928.
16. Church TS, Finley CE, Earnest CP, Kampert JB, Gibbons LW, Blair SN. Relative associations of fitness and fatness to fibrinogen, white blood cell count, uric acid and metabolic syndrome. Int J Obes Relat Metab Disord. 2002; 26: 805–813.[CrossRef][Medline] [Order article via Infotrieve]
17. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol. 2002; 22: 1869–1876.
18. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006; 295: 1412–1419.
19. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Womens Health Study: a randomized controlled trial. JAMA. 2005; 294: 47–55.
20. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Womens Health Study: a randomized controlled trial. JAMA. 2005; 294: 56–65.
21. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352: 1293–1304.
22. Wolf AM, Hunter DJ, Colditz GA, Manson JE, Stampfer MJ, Corsano KA, Rosner B, Kriska A, Willett WC. Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol. 1994; 23: 991–999.
23. Lee IM, Rexrode KM, Cook NR, Manson JE, Buring JE. Physical activity and coronary heart disease in women: is "no pain, no gain" passé? JAMA. 2001; 285: 1447–1454.
24. Rothman KJ, Greenland S. Measures of effect and association. In: Modern Epidemiology. Philadelphia, Pa: Lippincott Williams & Wilkins; 1998: 47–64.
25. Shishehbor MH, Litaker D, Pothier CE, Lauer MS. Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality. JAMA. 2006; 295: 784–792.
26. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. Stroke. 2003; 34: 2475–2481.
27. Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, Kromhout D. Physical activity and stroke: a meta-analysis of observational data. Int J Epidemiol. 2004; 33: 787–798.
28. Ivy JL. Role of insulin during exercise-induced glycogenesis in muscle: effect on cyclic AMP. Am J Physiol. 1977; 233: E509–E513.[Medline] [Order article via Infotrieve]
29. Dunn AL, Marcus BH, Kampert JB, Garcia ME, Kohl HW, Blair SN. Comparison of lifestyle and structured interventions to increase physical activity and cardiorespiratory fitness: a randomized trial. JAMA. 1999; 281: 327–334.
30. Jakicic JM, Marcus BH, Gallagher KI, Napolitano M, Lang W. Effect of exercise duration and intensity on weight loss in overweight, sedentary women: a randomized trial. JAMA. 2003; 290: 1323–1330.
31. Thompson PD, Buchner D, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, Blair SN, Costa F, Franklin B, Fletcher GF, Gordon NF, Pate RR, Rodriguez BL, Yancey AK, Wenger NK. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. Circulation. 2003; 107: 3109–116.
32. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol. 2005; 45: 1563–1569.
33. Ostrowski K, Hermann C, Bangash A, Schjerling P, Nielsen JN, Pedersen BK. A trauma-like elevation of plasma cytokines in humans in response to treadmill running. J Physiol. 1998; 513: 889–894.
34. Tisi PV, Hulse M, Chulakadabba A, Gosling P, Shearman CP. Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response? Eur J Vasc Endovasc Surg. 1997; 14: 344–350.[CrossRef][Medline] [Order article via Infotrieve]
35. Adamopoulos S, Parissis J, Kroupis C, Georgiadis M, Karatzas D, Karavolias G, Koniavitou K, Coats AJ, Kremastinos DT. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J. 2001; 22: 791–797.
36. Hamer M. The relative influences of fitness and fatness on inflammatory factors. Prev Med. 2006; 44: 3–11.[CrossRef][Medline] [Order article via Infotrieve]
37. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, Schoene N, Schuler G. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000; 342: 454–460.
38. Radak Z, Chung HY, Naito H, Takahashi R, Jung KJ, Kim HJ, Goto S. Age-associated increase in oxidative stress and nuclear factor kappaB activation are attenuated in rat liver by regular exercise. FASEB J. 2004; 18: 749–750.
39. McFarlin BK, Flynn MG, Phillips MD, Stewart LK, Timmerman KL. Chronic resistance exercise training improves natural killer cell activity in older women. J Gerontol A Biol Sci Med Sci. 2005; 60: 1315–1318.
40. Stewart LK, Flynn MG, Campbell WW, Craig BA, Robinson JP, McFarlin BK, Timmerman KL, Coen PM, Felker J, Talbert E. Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. Brain Behav Immun. 2005; 19: 389–397.[CrossRef][Medline] [Order article via Infotrieve]
41. Lauer MS, Froelicher V. Abnormal heart-rate recovery after exercise. Lancet. 2002; 360: 1176–1177.[Medline] [Order article via Infotrieve]
42. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001; 86: 3257–3265.
43. Zhao G, Zhang X, Xu X, Ochoa M, Hintze TH. Short-term exercise training enhances reflex cholinergic nitric oxide-dependent coronary vasodilation in conscious dogs. Circ Res. 1997; 80: 868–876.
44. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation. 2007; 39: 1423–1434.
| Footnotes |
|---|
Related Article:
Circulation 2007 116: 2095.
This article has been cited by other articles:
![]() |
P. van der Harst, S. J.L. Bakker, R. A. de Boer, B. H.R. Wolffenbuttel, T. Johnson, M. J. Caulfield, and G. Navis Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms Hum. Mol. Genet., January 15, 2010; 19(2): 387 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Magnussen and H. Watz Systemic Inflammation in Chronic Obstructive Pulmonary Disease and Asthma: Relation with Comorbidities Proceedings of the ATS, December 15, 2009; 6(8): 648 - 651. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.L. Gudmundsdottir, W.D. Flanders, and L.B. Augestad Physical activity and fertility in women: the North-Trondelag Health Study Hum. Reprod., December 1, 2009; 24(12): 3196 - 3204. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Seals, A. E. Walker, G. L. Pierce, and L. A. Lesniewski Habitual exercise and vascular ageing J. Physiol., December 1, 2009; 587(23): 5541 - 5549. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Joyner and D. J. Green Exercise protects the cardiovascular system: effects beyond traditional risk factors J. Physiol., December 1, 2009; 587(23): 5551 - 5558. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watz, B. Waschki, A. Kirsten, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, and H. Magnussen The Metabolic Syndrome in Patients With Chronic Bronchitis and COPD: Frequency and Associated Consequences for Systemic Inflammation and Physical Inactivity Chest, October 1, 2009; 136(4): 1039 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Ikonomidis, S Tzortzis, J Lekakis, I Paraskevaidis, I Andreadou, M Nikolaou, T Kaplanoglou, P Katsimbri, G Skarantavos, P Soucacos, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis Heart, September 15, 2009; 95(18): 1502 - 1507. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Leon and U. G. Bronas Pathophysiology of Coronary Heart Disease and Biological Mechanisms for the Cardioprotective Effects of Regular Aerobic Exercise American Journal of Lifestyle Medicine, September 1, 2009; 3(5): 379 - 385. [Abstract] [PDF] |
||||
![]() |
W M van Teeffelen, M F de Beus, A Mosterd, M L Bots, W L Mosterd, J Pool, P A Doevendans, and D E Grobbee Risk factors for exercise-related acute cardiac events. A case-control study Br. J. Sports Med., September 1, 2009; 43(9): 722 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
D S Lasserson Initial management of suspected transient cerebral ischaemia and stroke in primary care: implications of recent research Postgrad. Med. J., August 1, 2009; 85(1006): 422 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Tinken, D. H.J. Thijssen, N. Hopkins, M. A. Black, E. A. Dawson, C. T. Minson, S. C. Newcomer, M. H. Laughlin, N. T. Cable, and D. J. Green Impact of Shear Rate Modulation on Vascular Function in Humans Hypertension, August 1, 2009; 54(2): 278 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Djousse, I-M. Lee, J. E. Buring, and J. M. Gaziano Alcohol Consumption and Risk of Cardiovascular Disease and Death in Women: Potential Mediating Mechanisms Circulation, July 21, 2009; 120(3): 237 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Mestek Physical Activity, Blood Lipids, and Lipoproteins American Journal of Lifestyle Medicine, July 1, 2009; 3(4): 279 - 283. [Abstract] [PDF] |
||||
![]() |
T. Ohira, J. M. Peacock, H. Iso, L. E. Chambless, W. D. Rosamond, and A. R. Folsom Serum and Dietary Magnesium and Risk of Ischemic Stroke: The Atherosclerosis Risk in Communities Study Am. J. Epidemiol., June 15, 2009; 169(12): 1437 - 1444. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mascitelli, F. Pezzetta, and M. R. Goldstein Letter to the Editor American Journal of Lifestyle Medicine, March 1, 2009; 3(2): 164 - 164. [PDF] |
||||
![]() |
J. Shen and J. M. Ordovas Impact of Genetic and Environmental Factors on hsCRP Concentrations and Response to Therapeutic Agents Clin. Chem., February 1, 2009; 55(2): 256 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mora, K. Musunuru, and R. S. Blumenthal The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines Clin. Chem., February 1, 2009; 55(2): 219 - 228. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF] |
||||
![]() |
D. T. Smith, L. J. Carr, C. Dorozynski, and C. Gomashe Internet-delivered lifestyle physical activity intervention: limited inflammation and antioxidant capacity efficacy in overweight adults J Appl Physiol, January 1, 2009; 106(1): 49 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hamer and A. Steptoe Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women Am. J. Clinical Nutrition, January 1, 2009; 89(1): 85 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hamer, G. J. Molloy, and E. Stamatakis Psychological distress as a risk factor for cardiovascular events: pathophysiological and behavioral mechanisms. J. Am. Coll. Cardiol., December 16, 2008; 52(25): 2156 - 2162. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Ameredes and D. W. Michielli Commentary on Viewpoint: Exercise and cardiovascular risk reduction: Time to update the rationale for exercise? J Appl Physiol, August 1, 2008; 105(2): 769 - 769. [Full Text] [PDF] |
||||
![]() |
D. J. Green, G. O'Driscoll, M. J. Joyner, and N. T. Cable Exercise and cardiovascular risk reduction: Time to update the rationale for exercise? J Appl Physiol, August 1, 2008; 105(2): 766 - 768. [Full Text] [PDF] |
||||
![]() |
S. Mohlenkamp, N. Lehmann, F. Breuckmann, M. Brocker-Preuss, K. Nassenstein, M. Halle, T. Budde, K. Mann, J. Barkhausen, G. Heusch, et al. Running: the risk of coronary events : Prevalence and prognostic relevance of coronary atherosclerosis in marathon runners Eur. Heart J., August 1, 2008; 29(15): 1903 - 1910. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kokkinos Physical Activity and Cardiovascular Disease Prevention: Current Recommendations Angiology, August 1, 2008; 59(2_suppl): 26S - 29S. [Abstract] [PDF] |
||||
![]() |
S. S. Bassuk and J. E. Manson Lifestyle and Risk of Cardiovascular Disease and Type 2 Diabetes in Women: A Review of the Epidemiologic Evidence American Journal of Lifestyle Medicine, June 1, 2008; 2(3): 191 - 213. [Abstract] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |